•The European Commission granted marketing authorization for Trodelvy in combination with Keytruda for first-line metastatic triple-negative breast cancer.
•Vision Marine Technologies signed a letter of intent for a business combination with an undisclosed counterparty specializing in defense and UAV technologies.
•Counterparty shareholders are expected to own approximately 97.1% of the combined entity upon closing.
